The growing understanding of the underlying pathophysiological mechanisms has recently led to the investigation of substances interfering with the mammalian target of rapamycin (mTOR) pathway, e.g. Sirolimus, Everolimus, in patients with TSC [14]. This evidence concerns the gene MTOR and tuberous sclerosis.